Oral HPV Test Shows Potential for Predicting Oropharyngeal Cancer Risk
January 30th 2016Individuals with detectable human papillomavirus (HPV)-16 in their mouthwash samples were 22 times more likely to develop oropharyngeal cancer (OPC) than those without the type of virus, according to findings of a new study.
Weight-Loss Intervention Improves Fitness in Cancer Survivors
January 19th 2016Mounting research continues to show increased risk of cancer recurrence and death in obese individuals, but findings of a new study highlight the benefits of weight-loss interventions for overweight and obese cancer survivors.
Addressing Cisplatin's Late Effects in Testicular Cancer Survivors
January 16th 2016New research shows that survivors of testicular cancer may have an increased burden of morbidity after being treated with cisplatin-based chemotherapy, with obesity, neuropathies, and tinnitus and hearing loss among the most prevalent late effects.
Complete Guideline Adherence Low Among Young Hodgkin Lymphoma Survivors
January 12th 2016Despite national evidence- and consensus-based guidelines on posttreatment care, less than half of adolescents and young adults (AYAs) with Hodgkin lymphoma receive all of the recommended services within the first year after treatment, according to results of a pilot study being presented at the 2016 Cancer Survivorship Symposium.
After Doughnut Hole Closure, Oral Anticancer Drug Costs Still Too High for Many
January 7th 2016Studies show that cost is a factor in patient adherence to their oral anticancer medications, but the financial burden of oral chemotherapy drugs is projected to still be too high for millions of patients even when the Medicare Part D coverage gap, or “doughnut hole,†is fully closed.
Patient-Reported Symptoms May Improve Outcomes in Cancer Care
December 29th 2015Patients who self-reported their symptoms using a web-based system while undergoing chemotherapy had better health-related quality of life, fewer emergency room (ER) visits, remained on treatment longer, and survived longer than patients who received usual care.
FDA Approves Vistogard to Counteract Chemo Overdose, Toxicities
December 11th 2015The FDA has approved uridine triacetate (Vistogard) for the emergency treatment of adult and pediatric patients who had severe or life-threatening toxicities within 4 days of treatment following an overdose of 5-fluorouracil (5-FU) or capecitabine.
Information Empowers Patients With GI Malignancies
December 9th 2015Entering through the giant, inflatable colon, dozens of patients, caregivers, family members and providers gathered at the Georgetown University Hotel and Conference Center in Washington, DC, December 5 for the symposium, “Fighting a Smarter War Against Cancer.â€
Avoidable Colorectal Cancer Deaths Hit Low Socioeconomic Areas Hardest
December 4th 2015Disparities in colorectal cancer deaths have had a significant impact on the national economy, with areas of low socioeconomic status experiencing the greatest losses, according to a study by researchers at the Centers for Disease Control and Prevention (CDC).
Anthracycline Regimens May Worsen 'Chemobrain' in Breast Cancer Survivors
December 3rd 2015Patients with breast cancer who have received anthracycline-based (ANTHR) chemotherapy may be more likely to experience "chemobrain"-a cancer-related cognitive impairment that can affect memory, attention, and physical function-than those treated with nonanthracycline-based regimens.
Improving Outcomes in Lung Cancer With Multidisciplinary Care
December 3rd 2015Navigation is an essential component of quality care for patients with lung cancer and their family caregivers, and the Bonnie J. Addario Lung Cancer Foundation (ALCF) is working to improve lung cancer outcomes through its Community Hospital Center of Excellence (COE) program.
Preventive Mastectomy May Not Benefit, but Decision Tool Can Help
October 26th 2015Contralateral prophylactic mastectomies (CPM) have been a growing trend among women at average risk of breast cancer with a diagnosis of cancer in one breast, but the procedure is not medically recommended for this population.